Anti Inflammatory News and Research

RSS

NOXXON to commence multiple ascending dose study of MCP-1 targeting anti-inflammatory Spiegelmer NOX-E36

NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chemoattractant Protein-1 (MCP-1) targeting anti-inflammatory Spiegelmer®, NOX-E36. NOXXON plans to develop NOX-E36 for the treatment of diabetic nephropathy and other diabetes related complications.

7 Jul 2010

Winston submits NDA for CIVANEX to U.S. FDA

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its civamide (zucapsaicin) 0.075% cream, CIVANEX®, for the treatment of signs and symptoms of osteoarthritis of the knee.

7 Jul 2010

Use of NSAIDs do not increase risk of heart attack in elderly patients: Study

Commonly used painkillers like ibuprofen do not increase the risk of heart attack in the elderly population, according to a new study. Researchers found that the use of these drugs - also called non-steroidal anti-inflammatory drugs - was also associated with a lower risk of death although they are not sure why.

7 Jul 2010

Aquapharm Biodiscovery signs research agreement with AMRI

Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm's marine natural products library derived from its extensive collection of marine micro-organisms.

7 Jul 2010

AHRQ publishes new comparative effectiveness report on treatments for rotator cuff tears

Injuries to the rotator cuff are treatable, but it is unclear which treatment option - surgery or nonsurgical treatments such as exercise or medication - is best, according to a new comparative effectiveness report published by HHS' Agency for Healthcare Research and Quality.

6 Jul 2010

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs.

5 Jul 2010

MabCent finds extraordinary life forms in the Arctic

During its short existence the Centre on Marine Bioactives and Drug Discovery (MabCent) in Tromsø has analysed some 70,000 fractions of Arctic marine organisms. Patents on two molecules have been applied for and applications for another 20 will soon follow.

3 Jul 2010

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo Pharmaceuticals today announced the successful completion of the tender offer by its wholly owned subsidiary, HT Acquisition Corp., for all of the outstanding shares of common stock of HealthTronics, Inc..

3 Jul 2010

Cyanotech regains Nasdaq compliance

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced that it had received notice from the Nasdaq Stock Market on June 30, 2010 of full compliance with Listing Rules required for its continued listing on the The Nasdaq Capital Market.

3 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Plant extract effective against ulcerative colitis in mice

A South Dakota State University scientist's research shows an extract made from a food plant in the Brassica family was effective in alleviating signs of ulcerative colitis, an inflammatory bowel condition, in mice.

2 Jul 2010

Clinical study proves effectiveness of acupuncture for heart patients

Acupuncture can improve exercise tolerance in patients suffering from chronic heart failure. This was determined in a clinical pilot study by the team headed by Dr. Johannes Backs, physician and study director at the Department of Internal Medicine III (Cardiology, Angiology, and Pneumology - Medical Director: Professor Dr. Hugo Katus) of Heidelberg University Hospital.

2 Jul 2010

New asthma therapy shows promise for patients who do not respond to steroid treatments

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Investment report on BioElectronics

MicroStockProfit.com announces an investment report featuring BioElectronics Corp. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

1 Jul 2010

Nanostructured assemblies for dental application

Scientists are reporting an advance toward the next big treatment revolution in dentistry - the era in which root canal therapy brings diseased teeth back to life, rather than leaving a "non-vital" or dead tooth in the mouth. In a report in the monthly journal ACS Nano, they describe a first-of-its-kind, nano-sized dental film that shows early promise for achieving this long-sought goal.

1 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

Judge rules for Merck in state Vioxx lawsuit over Medicaid payments

A federal judge ruled in favor of Merck & Co. Tuesday in a lawsuit brought by Louisiana trying to recoup what it paid when Medicaid patients used the company's withdrawn painkiller Vioxx, The Associated Press reports. James R. Dugan II, "the lead attorney representing Louisiana, said his team would be meeting with state officials later this week to discuss appellate possibilities.

1 Jul 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.

30 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.

29 Jun 2010

Anti Inflammatory News and Research

NOXXON to commence multiple ascending dose study of MCP-1 targeting anti-inflammatory Spiegelmer NOX-E36

Winston submits NDA for CIVANEX to U.S. FDA

Use of NSAIDs do not increase risk of heart attack in elderly patients: Study

Aquapharm Biodiscovery signs research agreement with AMRI

AHRQ publishes new comparative effectiveness report on treatments for rotator cuff tears

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

MabCent finds extraordinary life forms in the Arctic

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Cyanotech regains Nasdaq compliance

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Plant extract effective against ulcerative colitis in mice

Clinical study proves effectiveness of acupuncture for heart patients

New asthma therapy shows promise for patients who do not respond to steroid treatments

Investment report on BioElectronics

Nanostructured assemblies for dental application

Endo responds to FDA Complete Response letter for FORTESTA NDA

Judge rules for Merck in state Vioxx lawsuit over Medicaid payments

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

AlphaRx regains all rights to Indaflex from Cypress Bioscience

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News